Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Change in Acquisitions & Divestments (2016 - 2025)

Historic Change in Acquisitions & Divestments for Rhythm Pharmaceuticals (RYTM) over the last 10 years, with Q3 2025 value amounting to $61.5 million.

  • Rhythm Pharmaceuticals' Change in Acquisitions & Divestments rose 3574.66% to $61.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $288.4 million, marking a year-over-year increase of 2198.0%. This contributed to the annual value of $260.6 million for FY2024, which is 2657.35% down from last year.
  • According to the latest figures from Q3 2025, Rhythm Pharmaceuticals' Change in Acquisitions & Divestments is $61.5 million, which was up 3574.66% from $81.0 million recorded in Q2 2025.
  • In the past 5 years, Rhythm Pharmaceuticals' Change in Acquisitions & Divestments ranged from a high of $156.7 million in Q3 2021 and a low of $45.3 million during Q3 2024
  • In the last 5 years, Rhythm Pharmaceuticals' Change in Acquisitions & Divestments had a median value of $69.0 million in 2021 and averaged $76.9 million.
  • In the last 5 years, Rhythm Pharmaceuticals' Change in Acquisitions & Divestments tumbled by 6075.52% in 2022 and then skyrocketed by 14411.76% in 2023.
  • Rhythm Pharmaceuticals' Change in Acquisitions & Divestments (Quarter) stood at $69.0 million in 2021, then dropped by 13.63% to $59.6 million in 2022, then grew by 6.12% to $63.3 million in 2023, then skyrocketed by 38.3% to $87.5 million in 2024, then decreased by 29.74% to $61.5 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $61.5 million for Q3 2025, versus $81.0 million for Q2 2025 and $58.3 million for Q1 2025.